Literature DB >> 23099356

Association between glycated haemoglobin and the risk of congestive heart failure in diabetes mellitus: systematic review and meta-analysis.

Sebhat Erqou1, Chee-Tin Christine Lee, Matthew Suffoletto, Justin B Echouffo-Tcheugui, Rudolf A de Boer, Joost P van Melle, Amanda I Adler.   

Abstract

BACKGROUND: Clinical trials to date have not provided definitive evidence regarding the effects of glucose lowering on the incidence of congestive heart failure (CHF). We synthesized available prospective epidemiological data on the association between glycaemia measured by haemoglobin A(1c) (HbA(1c)) and incident CHF in individuals with diabetes. METHODS AND
RESULTS: We searched electronic databases and reference lists of selected articles for relevant prospective epidemiological studies. We abstracted data from relevant studies using standardized forms and obtained additional data from investigators when required. We pooled study-specific relative risk estimates using random-effects model meta-analysis. Of the 1044 citations identified, we included 10 studies comprising 178 929 participants with diabetes and 14 176 incident CHF cases. Five studies included only patients with type 2 diabetes, four studies had predominantly patients with type 2 diabetes, and one study included only patients with type 1 diabetes. All studies except one showed an increased risk of CHF with higher HbA(1c). The overall adjusted risk ratio (RR) for CHF was 1.15 [95% confidence interval (CI) 1.10-1.21] for each percentage point higher HbA(1c). There was substantial heterogeneity across the 10 studies (I(2): 83%; 95% CI 69-91%; P < 0.001) not explained by available study-level characteristics such as study design or average HbA(1c) level. In seven studies reporting RRs with more than one degree of adjustment, the association was minimally altered after adjustment for several cardiovascular risk factors.
CONCLUSIONS: In observational studies of individuals with diabetes, a higher HbA(1c) level was associated with a significantly increased incidence of CHF.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099356     DOI: 10.1093/eurjhf/hfs156

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  22 in total

Review 1.  Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.

Authors:  Shilpa Vijayakumar; Muthiah Vaduganathan; Javed Butler
Journal:  Circulation       Date:  2018-03-06       Impact factor: 29.690

2.  Dysglycemia and incident heart failure among blacks: The jackson heart study.

Authors:  Justin B Echouffo-Tcheugui; Stanford E Mwasongwe; Solomon K Musani; Michael E Hall; Adolfo Correa; Adrian F Hernandez; Sherita H Golden; Robert J Mentz; Alain G Bertoni
Journal:  Am Heart J       Date:  2021-11-19       Impact factor: 4.749

Review 3.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

4.  HbA1c and heart failure risk among diabetic patients.

Authors:  Wenhui Zhao; Peter T Katzmarzyk; Ronald Horswell; Yujie Wang; Jolene Johnson; Gang Hu
Journal:  J Clin Endocrinol Metab       Date:  2013-01-01       Impact factor: 5.958

Review 5.  Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations.

Authors:  Cecilia C Low Wang; Connie N Hess; William R Hiatt; Allison B Goldfine
Journal:  Circulation       Date:  2016-06-14       Impact factor: 29.690

6.  Egg consumption, overall diet quality, and risk of type 2 diabetes and coronary heart disease: A pooling project of US prospective cohorts.

Authors:  Luc Djoussé; Guohai Zhou; Robyn L McClelland; Nanxun Ma; Xia Zhou; Edmond K Kabagambe; Sameera A Talegawkar; Suzanne E Judd; Mary L Biggs; Annette L Fitzpatrick; Cheryl R Clark; David R Gagnon; Lyn M Steffen; J Michael Gaziano; I-Min Lee; Julie E Buring; JoAnn E Manson
Journal:  Clin Nutr       Date:  2021-03-11       Impact factor: 7.643

7.  Assessing the linear and non-linear association of HbA1c with cardiovascular disease: a Mendelian randomisation study.

Authors:  Shan Luo; Shiu Lun Au Yeung; C Mary Schooling
Journal:  Diabetologia       Date:  2021-08-03       Impact factor: 10.122

Review 8.  Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.

Authors:  Utkarsh Ojha; Lenisse Reyes; Florence Eyenga; Diane Oumbe; Justyna Watkowska; Henock Saint-Jacques
Journal:  Am J Cardiovasc Drugs       Date:  2021-06-30       Impact factor: 3.571

Review 9.  Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects.

Authors:  Giuseppe Palmiero; Arturo Cesaro; Erica Vetrano; Pia Clara Pafundi; Raffaele Galiero; Alfredo Caturano; Elisabetta Moscarella; Felice Gragnano; Teresa Salvatore; Luca Rinaldi; Paolo Calabrò; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2021-05-30       Impact factor: 5.923

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.